Fig. 1
From: Drug and disease signature integration identifies synergistic combinations in glioblastoma
SynergySeq workflow for identifying synergistic drug combinations using disease discordance and drug concordance. a A disease signature is calculated by identifying the differentially expressed genes between tumor samples and same-tissue controls. b Transcriptional consensus signatures (TCS) are calculated for a reference small molecule and the LINCS L1000 small molecules. c The overlap between the reference TCS and the disease signature is calculated. d The LINCS L1000 small molecules are ranked to maximize the reversal of the disease signature. e The LINCS L1000 small molecules are plotted based on their similarity to the reference small molecule and the reversal of the disease signature
